$KYNB News

Kyntra Bio (NASDAQ:KYNB) Q1 Revenue Surges 180% as EPS Miss Tempers After-Hours Gains

Kyntra Bio, Inc. (KYNB) Q1 2026 Earnings Call Transcript

Kyntra Bio, Inc. 2026 Q1 - Results - Earnings Call Presentation

Kyntra Bio Q1 EPS $(3.76) Down From $1.15 YoY, Sales $3.738M Up From $2.739M YoY

Kyntra Bio (KYNB) Upgraded to Buy: Here's What You Should Know

RedChip's April 16 Virtual Investor Conference to Highlight Companies Driving the Next Wave of Biotech Innovation

Kyntra Bio to Present at the 25th Annual Needham Virtual Healthcare Conference

Kyntra Bio Inc (KYNB) Q4 2025 Earnings Call Highlights: Navigating Revenue Decline with ...

Kyntra Bio (KYNB) Q4 2025 Earnings Call Transcript

Kyntra Bio: Q4 Earnings Snapshot

Kyntra Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Kyntra Bio, Inc. (KYNB) Q4 2025 Earnings Call Transcript

Kyntra Bio, Inc. 2025 Q4 - Results - Earnings Call Presentation

Kyntra Bio Q4 EPS $(3.61) Beats $(3.71) Estimate, Sales $1.300M Miss $1.425M Estimate

Monte Rosa Therapeutics (GLUE) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Kyntra Bio (KYNB) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Kyntra Bio to Report Fourth Quarter and Full Year 2025 Financial Results

Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026

Kyntra Bio Reveals Data From The Investigator-Sponsored Phase 1b/2 Study Of FG-3246 In Combination With Enzalutamide In Patients With Metastatic Castration Resistant Prostate Cancer To Be Presented At ASCO GU 2026

Kyntra Bio Reveals Data From The Investigator-Sponsored Phase 1b/2 Study Of FG-3246 In Combination With Enzalutamide In Patients With Metastatic Castration Resistant Prostate Cancer To Be Presented At ASCO GU 2026